Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gruticibart for the Prevention of Early Catheter-related Thrombosis
NCT07498517Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Aug 2026
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Xisomab 3G3 in catheter-related thrombosis (CRT), sponsored by OHSU Knight Cancer Institute. Started Aug 2026; status: recruiting.
02
Drugs
Xisomab 3G3
03
Conditions
catheter-related thrombosis (CRT)
Beyond the preview
Go deeper on NCT07498517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498517.